Metastatic Esophageal or Gastric Cancer, Esophageal or Gastric Cancer research hub

A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

This phase 3 clinical trial is looking at a new combination of immunotherapy drugs given alongside chemotherapy. It aims to find out if this new combination helps people with untreated, advanced cancer of the stomach or food pipe live longer compared to the current standard immunotherapy and chemotherapy treatment.